m-40403 has been researched along with Kidney-Neoplasms* in 2 studies
2 other study(ies) available for m-40403 and Kidney-Neoplasms
| Article | Year |
|---|---|
A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects.
Interleukin-2 (IL-2) is used to treat metastatic renal cell carcinoma and malignant melanoma, but its use is limited by the severe hypotension it produces. We have shown here that M40403, a superoxide dismutase (SOD) mimetic, blocked IL-2-induced hypotension and allowed the dose of IL-2 to be increased in mice. The reversal of IL-2-mediated hypotension was associated with an increase in plasma catecholamines. In addition, M40403 increased lymphokine-activated killer (LAK) cell cytotoxicity in vitro and in vivo, through inhibition of macrophage superoxide production. Treatment of methylcholanthrene-induced (Meth A) ascites tumors with IL-2 and > or =3 mg per kg body weight M40403 induced 50% complete remissions lasting for more than 200 d, which was longer than those of untreated mice (15-d median survival) or mice treated with IL-2 alone (22-d median). Growth of subcutaneous implants of RENCA renal carcinoma was also inhibited by the combination of IL-2 and M40403. These results established that M40403 prevented IL-2 from causing dose-limiting hypotension, while enhancing its anticancer activity. Topics: Animals; Antineoplastic Agents; Catecholamines; Dose-Response Relationship, Drug; Female; Humans; Hypotension; Interleukin-2; Kidney Neoplasms; Killer Cells, Natural; Lymphocyte Activation; Macrophages; Manganese; Melanoma; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Molecular Mimicry; Molecular Structure; Organometallic Compounds; Superoxide Dismutase; Survival Rate | 2003 |
Biological drug duo delivers one-two tumor punch.
Topics: Animals; Antineoplastic Agents; Humans; Interleukin-2; Kidney Neoplasms; Manganese; Melanoma; Mice; Organometallic Compounds; Superoxides; Survival Rate | 2003 |